Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Solid Biosciences's SGT-003?
SGT-003 is a gene therapy commercialized by Solid Biosciences, with a leading Phase II program in Duchenne Muscular Dystrophy. According...
SGT-003 by Solid Biosciences for Duchenne Muscular Dystrophy: Likelihood of Approval
SGT-003 is under clinical development by Solid Biosciences and currently in Phase II for Duchenne Muscular Dystrophy. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Solid Biosciences's SGT-003?
SGT-003 is a gene therapy commercialized by Solid Biosciences, with a leading Phase II program in Duchenne Muscular Dystrophy. According...